Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat.com 5 Healthcare Plays Powering the Sector's Big ComebackWritten by Ryan Hasson. Published 10/9/2025. 
Key Points - After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
- A landmark deal between President Trump and Pfizer to lower drug prices under Medicaid sparked a sharp rally in the sector and boosted optimism for broader reform.
- With improving fundamentals and technical strength, major players like Pfizer, Eli Lilly, Merck, and UnitedHealth could lead the next leg higher for healthcare stocks.
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has returned just 7% over three years and 8.5% over five years, lagging the broader market. Even this year, XLV is up only 5.2% year-to-date, once again behind the S&P 500. But a new wave of catalysts could change that narrative. With the prospect of lower interest rates, a significant policy breakthrough on drug pricing, and renewed investor appetite for defensive, high-yielding sectors, healthcare may be positioned for a long-awaited turnaround. Gallup reports that two-thirds of Americans now view socialism favorably — a shocking shift that one analyst says signals a much deeper and more dangerous transformation underway. Porter Stansberry calls it The Final Displacement — a once-in-a-century realignment of technology, society, and economics that could create vast new wealth for some while devastating millions of others. His new documentary breaks down the warning signs, the accelerating pace of this change, and how to prepare before it reshapes the world around us. Click here to stream The Final Displacement for free Lower rates tend to favor dividend-paying, defensive names. As borrowing costs fall, capital often flows back toward stable, income-generating assets — precisely the kinds of companies that dominate the healthcare landscape. With policy relief and improving fundamentals across the board, the setup for a sector-wide rebound looks increasingly compelling. And this time, the spark came from a headline that few saw coming. A Policy Breakthrough Ignites the Sector Healthcare stocks rallied after President Donald Trump and Pfizer announced a landmark deal to lower prescription drug prices under Medicaid in exchange for tariff relief. Investors cheered the agreement, which was viewed as more balanced than punitive. In response, XLV surged over 5% in just two sessions — its best two-day performance since November 2020, when optimism about the vaccine first lifted the sector. The new Most-Favored-Nation (MFN) pricing framework ties U.S. Medicaid drug prices to the lowest prices paid by other developed nations. It's a historic move designed to reduce costs for patients without crushing pharmaceutical margins. In exchange for a three-year exemption from tariffs, Pfizer agreed to extend MFN pricing to all U.S. Medicaid programs, provide up to 80% discounts on select medications, repatriate foreign profits, and invest roughly $70 billion to expand U.S. manufacturing capacity. The company also joined TrumpRx.gov, a new federal platform designed to give Americans direct access to lower-cost medicines. The deal brings much-needed clarity after years of regulatory uncertainty and may pave the way for similar agreements with other major players. What was once seen as a looming policy risk could now evolve into a manageable, growth-friendly framework. Amid this optimism, several healthcare names have emerged as both high-yield opportunities and long-term value plays for investors betting on a sustained recovery. Pfizer: Momentum Reignited in a Long-Time Laggard Pfizer Inc. (NYSE: PFE) was the clear winner of the week, with shares soaring more than 15% following the announcement. That was its strongest weekly performance in years. After spending much of 2024 and early 2025 near multi-year lows, the stock is finally showing signs of life. In Q2 2025, Pfizer exceeded both revenue and earnings estimates, reporting earnings per share of $0.78, surpassing expectations of $0.58. Revenue climbed 10.3% year-over-year to $14.65 billion, also ahead of forecasts. At current levels, the stock offers one of the most compelling value propositions among large-cap pharmaceutical companies. With a forward P/E of just 8.7 and a dividend yield of 6.25%, it combines deep value with reliable income — a potent mix in an evolving rate environment. After years of stagnation, this policy breakthrough and an improving earnings trajectory may have reignited momentum for Pfizer and the broader healthcare space. Eli Lilly: A Long-Term Leader Setting Up for Another Breakout Eli Lilly and Company (NYSE: LLY) remains the sector's growth powerhouse. The stock is up 8.7% year-to-date, but its longer-term record is extraordinary, reflecting a 151% gain over the past three years fueled by blockbuster demand for its diabetes and obesity treatments. Technically, Lilly's setup looks bullish. After a 16% surge last week, shares are consolidating just below the key $900 resistance level. A decisive move above that mark could confirm a breakout and continue its long-term uptrend, after a sustained pullback earlier in the year. While the dividend yield of 0.71% is modest, Lilly's strength lies in consistency, innovation, and execution. Analysts maintain a Moderate Buy rating, with a consensus target suggesting more than 11% upside from current levels. For investors seeking dependable growth in a sector known for defensive income, Lilly stands out as a potential leader for the next phase of the healthcare cycle. UnitedHealth Group: Rebounding Strongly After a Steep Slide UnitedHealth's recovery has been sharp and decisive. After a difficult start to the year, UnitedHealth Group Incorporated (NYSE: UNH) has rebounded more than 50% from its 52-week low, driven by renewed institutional interest and a notable vote of confidence from Warren Buffett's Berkshire Hathaway. Despite remaining in the red year-to-date, UnitedHealth's technicals have improved dramatically. The stock has broken its downtrend, established higher lows, and continues to regain momentum. With strong margins, steady growth, and a dividend yield of 2.45%, the company remains a cornerstone in the healthcare insurance space. As investors shift back toward stability and yield, UnitedHealth is well-positioned to become one of the leaders in the sector's next leg higher. Merck: Value, Yield, and a Breakout in the Making Merck & Co., Inc. (NYSE: MRK) is showing renewed strength after months of consolidation. The stock rallied 13.5% last week, breaking above a multi-month base and reclaiming key resistance near $85 — a potential signal that a trend reversal is underway. In its second quarter, Merck delivered EPS of $2.13, beating estimates by $0.10 on revenue of $15.81 billion. Though revenue was slightly below forecasts, the results reaffirmed the company's earnings resilience and operational consistency. With a forward P/E of just 9.27 and a dividend yield of 3.6%, Merck offers both value and income. Analysts anticipate nearly 20% upside from current levels, with a consensus target price of $106.41. If shares can maintain momentum above $90, the stock could confirm a long-term bottom and extend its recovery into 2026. The Healthcare Sector ETF: XLV's Bullish Reversal Gains Steam For those seeking broad exposure, the Health Care Select Sector SPDR Fund (NYSEARCA: XLV) remains the most efficient way to play the recovery theme. The ETF, with a 1.68% dividend yield, provides diversified access to sector leaders, including Eli Lilly, Johnson & Johnson, UnitedHealth, Merck, Amgen, Pfizer, and AbbVie. Last week, XLV closed up nearly 7%, breaking above its 200-day moving average — a strong technical confirmation that sector momentum is shifting. On a longer-term monthly chart, XLV has confirmed a higher low near $130, setting the stage for a potential retest of resistance around $150. If the ETF can hold above that level, a move toward its all-time high near $160 looks increasingly likely. For investors seeking a balance between value, growth, and income, XLV offers a straightforward, diversified approach to capturing the sector's resurgence. Healthcare Enters New Stage of Strength After years of lagging the broader market, healthcare may be entering a new phase of strength. Falling interest rates, a more constructive policy backdrop, and improving fundamentals across major players are combining to reignite investor interest. Pfizer's deal may have been the immediate spark, but the broader takeaway is clear: sentiment toward healthcare stocks has shifted. What was once viewed as a politically burdened, slow-growth sector is now reemerging as a value-driven, income-generating opportunity with real upside potential. For investors positioning themselves ahead of a potential multi-year recovery, Pfizer, Merck, and UnitedHealth stand out for their value and yield, while Eli Lilly offers growth leadership. And for those who prefer simplicity and diversification, XLV remains the go-to vehicle to capture the sector's resurgence. After years in the shadows, healthcare might finally be ready to challenge for leadership. For long-term investors, that could make now a potentially opportune time to buy and hold.
| 
Post a Comment
Post a Comment